A Novel Biomarker SNX9 For Chronic Inflammation and Associated Immunosuppression and a new regulator of T-Cell Expression and receptor expression and function
A new Improdias` patent was granted in Israel. The patent defines a new biomarker related to chronic inflammation and associated Immunosuppression with a different regulatory path than our previous patented biomarkers in order to better define the immune status of patients.